Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Janet Zayas
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States; Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, United States
Sunil K Singh
Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, United States
Kaylee Delgado
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Stephen J Wood
Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, United States
Mohamed F Mohamed
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Dulce M Frausto
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Yasmeen A Albalawi
Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, United States
Thea P Price
Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, United States
Ricardo Estupinian
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Eileena F Giurini
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Timothy M Kuzel
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Andrew Zloza
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States
Jochen Reiser
Department of Medicine, Rush University Medical Center, Chicago, United States
Department of Medicine, Rush University Medical Center, Chicago, United States; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, United States; Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, United States
Infection is a major co-morbidity that contributes to impaired healing in diabetic wounds. Although impairments in diabetic neutrophils have been blamed for this co-morbidity, what causes these impairments and whether they can be overcome, remain largely unclear. Diabetic neutrophils, isolated from diabetic individuals, exhibit chemotaxis impairment but this peculiar functional impairment has been largely ignored because it appears to contradict the clinical findings which blame excessive neutrophil influx as a major impediment to healing in chronic diabetic ulcers. Here, we report that exposure to glucose in diabetic range results in impaired chemotaxis signaling through the formyl peptide receptor (FPR) in neutrophils, culminating in reduced chemotaxis and delayed neutrophil trafficking in the wound of Leprdb (db/db) type two diabetic mice, rendering diabetic wound vulnerable to infection. We further show that at least some auxiliary receptors remain functional under diabetic conditions and their engagement by the pro-inflammatory cytokine CCL3, overrides the requirement for FPR signaling and substantially improves infection control by jumpstarting the neutrophil trafficking toward infection, and stimulates healing in diabetic wound. We posit that CCL3 may have therapeutic potential for the treatment of diabetic foot ulcers if it is applied topically after the surgical debridement process which is intended to reset chronic ulcers into acute fresh wounds.